- 1.
Perälä
J, Suvisaari
J, Saarni
SI, Kuoppasalmi
K, Isometsä
E, Pirkola
S, et al.
Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry
2007;64:19–28. 10.1001/archpsyc.64.1.19 [
PubMed: 17199051] [
CrossRef]
- 2.
Walker
ER, McGee
RE, Druss
BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry
2015;72:334–41. 10.1001/jamapsychiatry.2014.2502 [
PMC free article: PMC4461039] [
PubMed: 25671328] [
CrossRef]
- 3.
Osborn
DJ, Levy
G, Nazareth
I, Petersen
I, Islam
A, King
MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s general practice research database. Arch Gen Psychiatry
2007;64:242–9. 10.1001/archpsyc.64.2.242 [
PubMed: 17283292] [
CrossRef]
- 4.
Lawrence
DM, Holman
CD, Jablensky
AV, Hobbs
MS. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980–1998. Br J Psychiatry
2003;182:31–6. 10.1192/bjp.182.1.31 [
PubMed: 12509315] [
CrossRef]
- 5.
Hennekens
CH, Hennekens
AR, Hollar
D, Casey
DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J
2005;150:1115–21. 10.1016/j.ahj.2005.02.007 [
PubMed: 16338246] [
CrossRef]
- 6.
Osborn
D, Levy
G, Nazareth
I, King
M. Suicide and severe mental illnesses. Cohort study within the UK general practice research database. Schizophr Res
2008;99:134–8. 10.1016/j.schres.2007.11.025 [
PubMed: 18155881] [
CrossRef]
- 7.
Hayes
JF, Marston
L, Walters
K, King
MB, Osborn
DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry
2017;211:175–81. 10.1192/bjp.bp.117.202606 [
PMC free article: PMC5579328] [
PubMed: 28684403] [
CrossRef]
- 8.
Olfson
M, Gerhard
T, Huang
C, Crystal
S, Stroup
TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry
2015;72:1172–81. 10.1001/jamapsychiatry.2015.1737 [
PubMed: 26509694] [
CrossRef]
- 9.
Correll
CU, Robinson
DG, Schooler
NR, Brunette
MF, Mueser
KT, Rosenheck
RA, et al.
Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry
2014;71:1350–63. 10.1001/jamapsychiatry.2014.1314 [
PubMed: 25321337] [
CrossRef]
- 10.
Osborn
DP, Nazareth
I, King
MB. Risk for coronary heart disease in people with severe mental illness: cross-sectional comparative study in primary care. Br J Psychiatry
2006;188:271–7. 10.1192/bjp.bp.104.008060 [
PubMed: 16507970] [
CrossRef]
- 11.
Osborn
DP, Wright
CA, Levy
G, King
MB, Deo
R, Nazareth
I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry
2008;8:84. 10.1186/1471-244X-8-84 [
PMC free article: PMC2570660] [
PubMed: 18817565] [
CrossRef]
- 12.
Nenke
MA, Hahn
LA, Thompson
CH, Liu
D, Galletly
CA. Psychosis and cardiovascular disease: is diet the missing link?
Schizophr Res
2015;161:465–70. 10.1016/j.schres.2014.12.012 [
PubMed: 25560938] [
CrossRef]
- 13.
Osborn
DP, Nazareth
I, King
MB. Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness: a cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol
2007;42:787–93. 10.1007/s00127-007-0247-3 [
PubMed: 17721669] [
CrossRef]
- 14.
- 15.
Thakore
JH. Metabolic syndrome and schizophrenia. Br J Psychiatr
2005;186:455–6. 10.1192/bjp.186.6.455 [
PubMed: 15928352] [
CrossRef]
- 16.
Kontopantelis
E, Olier
I, Planner
C, Reeves
D, Ashcroft
DM, Gask
L, et al.
Primary care consultation rates among people with and without severe mental illness: a UK cohort study using the Clinical Practice Research Datalink. BMJ Open
2015;5:e008650. 10.1136/bmjopen-2015-008650 [
PMC free article: PMC4691766] [
PubMed: 26674496] [
CrossRef]
- 17.
National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management. NICE Guideline (CG178). London: NICE; 2014.
- 18.
National Institute for Health and Care Excellence (NICE). Bipolar Disorder: Assessment and Management. NICE Guideline (CG185). London: NICE; 2016 (update).
- 19.
Barnes
TR, Paton
C, Hancock
E, Cavanagh
MR, Taylor
D, Lelliott
P, UK Prescribing Observatory for Mental Health. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand
2008;118:26–33. 10.1111/j.1600-0447.2008.01203.x [
PubMed: 18582345] [
CrossRef]
- 20.
- 21.
Osborn
DP, King
MB, Nazareth
I. Participation in screening for cardiovascular risk by people with schizophrenia or similar mental illnesses: cross sectional study in general practice. BMJ
2003;326:1122–3. 10.1136/bmj.326.7399.1122 [
PMC free article: PMC156006] [
PubMed: 12763984] [
CrossRef]
- 22.
Hardy
S, Gray
R. Is the use of an invitation letter effective in prompting patients with severe mental illness to attend a primary care physical health check?
Prim Health Care Res Dev
2012;13:347–52. 10.1017/S1463423612000023 [
PubMed: 22340012] [
CrossRef]
- 23.
Roberts
L, Roalfe
A, Wilson
S, Lester
H. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract
2007;24:34–40. 10.1093/fampra/cml054 [
PubMed: 17062587] [
CrossRef]
- 24.
Martin
JL, Lowrie
R, McConnachie
A, McLean
G, Mair
F, Mercer
SW, Smith
DJ. Physical health indicators in major mental illness: analysis of QOF data across UK general practice. Br J Gen Pract
2014;64:e649–56. 10.3399/bjgp14X681829 [
PMC free article: PMC4173728] [
PubMed: 25267051] [
CrossRef]
- 25.
National Institute for Health and Care Excellence (NICE). Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. NICE Guideline (CG181). London: NICE; 2016 (update).
- 26.
Brindle
P, May
M, Gill
P, Cappuccio
F, D’Agostino
R, Fischbacher
C, Ebrahim
S. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart
2006;92:1595–602. 10.1136/hrt.2006.092346 [
PMC free article: PMC1861244] [
PubMed: 16762981] [
CrossRef]
- 27.
De Hert
M, Kalnicka
D, van Winkel
R, Wampers
M, Hanssens
L, Van Eyck
D, et al.
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry
2006;67:1889–96. 10.4088/JCP.v67n1208 [
PubMed: 17194266] [
CrossRef]
- 28.
Vincenzi
B, Stock
S, Borba
CP, Cleary
SM, Oppenheim
CE, Petruzzi
LJ, et al.
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res
2014;159:395–403. 10.1016/j.schres.2014.08.021 [
PMC free article: PMC4311769] [
PubMed: 25261882] [
CrossRef]
- 29.
Baker
A, Richmond
R, Haile
M, Lewin
TJ, Carr
VJ, Taylor
RL, et al.
A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry
2006;163:1934–42. 10.1176/ajp.2006.163.11.1934 [
PubMed: 17074945] [
CrossRef]
- 30.
Naslund
JA, Aschbrenner
KA, Scherer
EA, Pratt
SI, Wolfe
RS, Bartels
SJ. Lifestyle intervention for people with severe obesity and serious mental illness. Am J Prev Med
2016;50:145–53. 10.1016/j.amepre.2015.07.012 [
PMC free article: PMC4718763] [
PubMed: 26385164] [
CrossRef]
- 31.
- 32.
Osborn
DP, Nazareth
I, Wright
CA, King
MB. Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams. BMC Health Serv Res
2010;10:61. 10.1186/1472-6963-10-61 [
PMC free article: PMC2850904] [
PubMed: 20219096] [
CrossRef]
- 33.
Bruins
J, Jörg
F, Bruggeman
R, Slooff
C, Corpeleijn
E, Pijnenborg
M. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLOS ONE
2014;9:e112276. 10.1371/journal.pone.0112276 [
PMC free article: PMC4256304] [
PubMed: 25474313] [
CrossRef]
- 34.
Baxter
AJ, Harris
MG, Khatib
Y, Brugha
TS, Bien
H, Bhui
K. Reducing excess mortality due to chronic disease in people with severe mental illness: meta-review of health interventions. Br J Psychiatry
2016;208:322–9. 10.1192/bjp.bp.115.163170 [
PubMed: 26941263] [
CrossRef]
- 35.
Bauer
IE, Gálvez
JF, Hamilton
JE, Balanzá-Martínez
V, Zunta-Soares
GB, Soares
JC, Meyer
TD. Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: a systematic review. J Psychiatr Res
2016;74:1–7. 10.1016/j.jpsychires.2015.12.006 [
PMC free article: PMC4744495] [
PubMed: 26724541] [
CrossRef]
- 36.
Kilbourne
AM, Barbaresso
MM, Lai
Z, Nord
KM, Bramlet
M, Goodrich
DE, et al.
Improving physical health in patients with chronic mental disorders: twelve-month results from a randomized controlled collaborative care trial. J Clin Psychiatry
2017;78:129–37. 10.4088/JCP.15m10301 [
PMC free article: PMC5272777] [
PubMed: 27780336] [
CrossRef]
- 37.
Osborn
DP, Hardoon
S, Omar
RZ, Holt
RI, King
M, Larsen
J, et al.
Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry
2015;72:143–51. 10.1001/jamapsychiatry.2014.2133 [
PMC free article: PMC4353842] [
PubMed: 25536289] [
CrossRef]
- 38.
Shiers
DE, Rafi
I, Cooper
SJ, Holt
RIG. 2014 Update (With Acknowledgement to the Late Helen Lester for her Contribution to the Original 2012 Version) Positive Cardiometabolic Health Resource: An Intervention Framework for Patients with Psychosis and Schizophrenia. London: Royal College of Psychiatrists; 2014 update.
- 39.
Cooper
SJ, Reynolds
GP, Barnes
T, England
E, Haddad
PM, Heald
A, et al.
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol
2016;30:717–48. 10.1177/0269881116645254 [
PubMed: 27147592] [
CrossRef]
- 40.
Zomer
E, Osborn
D, Nazareth
I, Blackburn
R, Burton
A, Hardoon
S, et al.
Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE). BMJ Open
2017;7:e018181. 10.1136/bmjopen-2017-018181 [
PMC free article: PMC5588956] [
PubMed: 28877952] [
CrossRef]
- 41.
D’Agostino
RB, Vasan
RS, Pencina
MJ, Wolf
PA, Cobain
M, Massaro
JM, Kannel
WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation
2008;117:743–53. 10.1161/CIRCULATIONAHA.107.699579 [
PubMed: 18212285] [
CrossRef]
- 42.
Wilson
PW, D’Agostino
R, Bhatt
DL, Eagle
K, Pencina
MJ, Smith
SC, et al.
An international model to predict recurrent cardiovascular disease. Am J Med
2012;125:695–703.e1. 10.1016/j.amjmed.2012.01.014 [
PubMed: 22727237] [
CrossRef]
- 43.
Taylor
F, Huffman
MD, Macedo
AF, Moore
TH, Burke
M, Davey Smith
G, et al.
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev
2013;1:CD004816. 10.1002/14651858.CD004816.pub5 [
PMC free article: PMC6481400] [
PubMed: 23440795] [
CrossRef]
- 44.
Curtis
L. Unit Costs of Health and Social Care 2013. Canterbury: PSSRU, University of Kent; 2013.
- 45.
National Institute for Health and Care Excellence (NICE). Process and Methods Guides: Guide to the Methods of Technology Appraisal. NICE Guideline. London: NICE; 2013.
- 46.
Briggs
A, Wild
D, Lees
M, Reaney
M, Dursun
S, Parry
D, Mukherjee
J. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes
2008;6:105. 10.1186/1477-7525-6-105 [
PMC free article: PMC2613374] [
PubMed: 19040721] [
CrossRef]
- 47.
Briggs
A CK, Sculpher
M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
- 48.
Burton
A, Osborn
D, Atkins
L, Michie
S, Gray
B, Stevenson
F, et al.
Lowering Cardiovascular Disease Risk for People with Severe Mental Illnesses in Primary Care: A Focus Group Study. PLOS ONE
2015;10:e0136603. 10.1371/journal.pone.0136603 [
PMC free article: PMC4552729] [
PubMed: 26317516] [
CrossRef]
- 49.
- 50.
Ritchie
J, Lewis
J. Qualitative Research Practice: A Guide for Social Science Students and Researchers. London: Sage; 2003.
- 51.
Burton
A, Walters
K, Atkins
L, Howard
M, Michie
S, Peveler
R, et al.
Barriers, facilitators, and effective interventions for lowering cardiovascular disease risk in people with severe mental illnesses: evidence from a systematic review and focus group study. Lancet
2016;388(Suppl. 2):30. URL:
www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)32266-8.pdf (accessed September 2018).
- 52.
Banham
L, Gilbody
S. Smoking cessation in severe mental illness: what works?
Addiction
2010;105:1176–89. 10.1111/j.1360-0443.2010.02946.x [
PubMed: 20491721] [
CrossRef]
- 53.
Happell
B, Davies
C, Scott
D. Health behaviour interventions to improve physical health in individuals diagnosed with a mental illness: a systematic review. Int J Ment Health Nurs
2012;21:236–47. 10.1111/j.1447-0349.2012.00816.x [
PubMed: 22533331] [
CrossRef]
- 54.
Tolliver
BK, McRae
AL, Sonne
SC, Brady
KT. Safety and tolerability of acamprosate in alcohol-dependent individuals with bipolar disorder: an open-label pilot study. Addict Disord Their Treat
2009;8:33. 10.1097/ADT.0b013e31816719df [
CrossRef]
- 55.
Petrakis
IL, Nich
C, Ralevski
E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull
2006;32:644–54. 10.1093/schbul/sbl010 [
PMC free article: PMC2632271] [
PubMed: 16887890] [
CrossRef]
- 56.
McElroy
SL, Frye
MA, Altshuler
LL, Suppes
T, Hellemann
G, Black
D, et al.
A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord
2007;9:426–34. 10.1111/j.1399-5618.2007.00488.x [
PubMed: 17547588] [
CrossRef]
- 57.
Roy Chengappa
KN, Schwarzman
LK, Hulihan
JF, Xiang
J, Rosenthal
NR, Clinical Affairs Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry
2006;67:1698–706. 10.4088/JCP.v67n1105 [
PubMed: 17196048] [
CrossRef]
- 58.
McElroy
SL, Winstanley
E, Mori
N, Martens
B, McCoy
J, Moeller
D, et al.
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol
2012;32:165–72. 10.1097/JCP.0b013e3182488758 [
PubMed: 22367654] [
CrossRef]
- 59.
Ghanizadeh
A, Nikseresht
MS, Sahraian
A. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr Res
2013;147:110–15. 10.1016/j.schres.2013.03.021 [
PubMed: 23583010] [
CrossRef]
- 60.
- 61.
Afshar
H, Roohafza
H, Mousavi
G, Golchin
S, Toghianifar
N, Sadeghi
M, Talaei
M. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol
2009;23:157–62. 10.1177/0269881108089816 [
PubMed: 18515465] [
CrossRef]
- 62.
Álvarez-Jiménez
M, Martínez-García
O, Pérez-Iglesias
R, Ramírez
ML, Vázquez-Barquero
JL, Crespo-Facorro
B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res
2010;116:16–19. 10.1016/j.schres.2009.10.012 [
PubMed: 19896336] [
CrossRef]
- 63.
Wu
RR, Zhao
JP, Jin
H, Shao
P, Fang
MS, Guo
XF, et al.
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA
2008;299:185–93. 10.1001/jama.2007.56-b [
PubMed: 18182600] [
CrossRef]
- 64.
Ellinger
LK, Ipema
HJ, Stachnik
JM. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. Ann Pharmacother
2010;44:668–79. 10.1345/aph.1M550 [
PubMed: 20233913] [
CrossRef]
- 65.
Ball
MP, Warren
KR, Feldman
S, McMahon
RP, Kelly
DL, Buchanan
RW. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses
2011;5:17–25. 10.3371/CSRP.5.1.3 [
PubMed: 21459735] [
CrossRef]
- 66.
Borba
CP, Fan
X, Copeland
PM, Paiva
A, Freudenreich
O, Henderson
DC. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol
2011;31:653–8. 10.1097/JCP.0b013e31822bb573 [
PMC free article: PMC3725551] [
PubMed: 21869685] [
CrossRef]
- 67.
Roy Chengappa
K, Kupfer
DJ, Parepally
H, John
V, Basu
R, Buttenfield
J, et al.
A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord
2007;9:609–17. 10.1111/j.1399-5618.2007.00506.x [
PubMed: 17845276] [
CrossRef]
- 68.
Elmslie
JL, Porter
RJ, Joyce
PR, Hunt
PJ, Mann
JI. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord
2006;8:503–7. 10.1111/j.1399-5618.2006.00345.x [
PubMed: 17042889] [
CrossRef]
- 69.
Henderson
DC, Freudenreich
O, Borba
CP, Wang
X, Copeland
PM, Macklin
E, et al.
Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res
2011;130:53–6. 10.1016/j.schres.2011.04.009 [
PubMed: 21565464] [
CrossRef]
- 70.
Narula
PK, Rehan
HS, Unni
KE, Gupta
N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res
2010;118:218–23. 10.1016/j.schres.2010.02.001 [
PubMed: 20207521] [
CrossRef]
- 71.
Jarskog
LF, Hamer
RM, Catellier
DJ, Stewart
DD, Lavange
L, Ray
N, et al.
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry
2013;170:1032–40. 10.1176/appi.ajp.2013.12010127 [
PMC free article: PMC3874085] [
PubMed: 23846733] [
CrossRef]
- 72.
Poyurovsky
M, Fuchs
C, Pashinian
A, Levi
A, Weizman
R, Weizman
A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology
2013;226:615–22. 10.1007/s00213-012-2935-2 [
PubMed: 23239133] [
CrossRef]
- 73.
Smith
RC, Jin
H, Li
C, Bark
N, Shekhar
A, Dwivedi
S, et al.
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res
2013;143:18–24. 10.1016/j.schres.2012.10.023 [
PubMed: 23200554] [
CrossRef]
- 74.
Vancampfort
D, Knapen
J, De Hert
M, van Winkel
R, Deckx
S, Maurissen
K, et al.
Cardiometabolic effects of physical activity interventions for people with schizophrenia. Phys Ther Rev
2009;14:388–98. 10.1179/108331909X12540993898053 [
CrossRef]
- 75.
- 76.
Verhaeghe
N, De Maeseneer
J, Maes
L, Van Heeringen
C, Annemans
L. Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act
2011;8:28. 10.1186/1479-5868-8-28 [
PMC free article: PMC3094265] [
PubMed: 21481247] [
CrossRef]
- 77.
Gabriele
JM, Dubbert
PM, Reeves
RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obes Rev
2009;10:442–55. 10.1111/j.1467-789X.2009.00570.x [
PubMed: 19389059] [
CrossRef]
- 78.
Álvarez-Jiménez
M, Hetrick
SE, González-Blanch
C, Gleeson
JF, McGorry
PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry
2008;193:101–7. 10.1192/bjp.bp.107.042853 [
PubMed: 18669990] [
CrossRef]
- 79.
Cordes
J, Thunker
J, Regenbrecht
G, Zielasek
J, Correll
CU, Schmidt-Kraepelin
C, et al.
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. World J Biol Psychiatr
2011;11:1–13. [
PubMed: 21745127]
- 80.
Iglesias-García
C, Toimil-Iglesias
A, Alonso-Villa
MJ. Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia. J Psychiatr Ment Health Nurs
2010;17:849–51. 10.1111/j.1365-2850.2010.01590.x [
PubMed: 21077409] [
CrossRef]
- 81.
Marzolini
S, Jensen
B, Melville
P. Feasibility and effects of a group-based resistance and aerobic exercise program for individuals with severe schizophrenia: a multidisciplinary approach. Ment Health Phys Act
2009;2:29–36. 10.1016/j.mhpa.2008.11.001 [
CrossRef]
- 82.
McCreadie
RG, Kelly
C, Connolly
M, Williams
S, Baxter
G, Lean
M, Paterson
JR. Dietary improvement in people with schizophrenia: randomised controlled trial. Br J Psychiatry
2005;187:346–51. 10.1192/bjp.187.4.346 [
PubMed: 16199794] [
CrossRef]
- 83.
Methapatara
W, Srisurapanont
M. Pedometer walking plus motivational interviewing program for Thai schizophrenic patients with obesity or overweight: a 12-week, randomized, controlled trial. Psychiatry Clin Neurosci
2011;65:374–80. 10.1111/j.1440-1819.2011.02225.x [
PubMed: 21682813] [
CrossRef]
- 84.
Usher
K, Park
T, Foster
K, Buettner
P. A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics. J Adv Nurs
2013;69:1539–48. 10.1111/jan.12012 [
PMC free article: PMC3798090] [
PubMed: 22973945] [
CrossRef]
- 85.
Daumit
GL, Dickerson
FB, Wang
NY, Dalcin
A, Jerome
GJ, Anderson
CA, et al.
A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med
2013;368:1594–602. 10.1056/NEJMoa1214530 [
PMC free article: PMC3743095] [
PubMed: 23517118] [
CrossRef]
- 86.
Ratliff
JC, Palmese
LB, Tonizzo
KM, Chwastiak
L, Tek
C. Contingency management for the treatment of antipsychotic-induced weight gain: a randomized controlled pilot study. Obes Facts
2012;5:919–27. 10.1159/000345975 [
PMC free article: PMC6902254] [
PubMed: 23296213] [
CrossRef]
- 87.
Scocco
P, Longo
R, Caon
F. Weight change in treatment with olanzapine and a psychoeducational approach. Eat Behav
2006;7:115–24. 10.1016/j.eatbeh.2005.08.003 [
PubMed: 16600840] [
CrossRef]
- 88.
Jean-Baptiste
M, Tek
C, Liskov
E, Chakunta
UR, Nicholls
S, Hassan
AQ, et al.
A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res
2007;96:198–205. 10.1016/j.schres.2007.05.022 [
PubMed: 17628437] [
CrossRef]
- 89.
Ferron
JC, Alterman
AI, McHugo
GJ, Brunette
MF, Drake
RE. A review of research on smoking cessation interventions for adults with schizophrenia spectrum disorders. Ment Health Subst Use
2009;2:64–79. 10.1080/17523280802593327 [
CrossRef]
- 90.
Chou
KR, Chen
R, Lee
JF, Ku
CH, Lu
RB. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud
2004;41:321–30. 10.1016/j.ijnurstu.2003.07.001 [
PubMed: 14967189] [
CrossRef]
- 91.
Petrakis
IL, O’Malley
S, Rounsaville
B, Poling
J, McHugh-Strong
C, Krystal
JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology
2004;172:291–7. 10.1007/s00213-003-1658-9 [
PubMed: 14634716] [
CrossRef]
- 92.
Brown
ES, Carmody
TJ, Schmitz
JM, Caetano
R, Adinoff
B, Swann
AC, John Rush
A. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res
2009;33:1863–9. 10.1111/j.1530-0277.2009.01024.x [
PMC free article: PMC3040070] [
PubMed: 19673746] [
CrossRef]
- 93.
Ralevski
E, O’Brien
E, Jane
JS, Dwan
R, Dean
E, Edens
E, et al.
Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. J Dual Diagn
2011;7:64–73. 10.1080/15504263.2011.569440 [
PubMed: 26954912] [
CrossRef]
- 94.
Cleary
M, Hunt
G, Matheson
S, Siegfried
N, Walter
G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev
2008;1:CD001088. 10.1002/14651858.CD001088.pub2 [
PubMed: 18253984] [
CrossRef]
- 95.
- 96.
Bonfioli
E, Berti
L, Goss
C, Muraro
F, Burti
L. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry
2012;12:78. 10.1186/1471-244X-12-78 [
PMC free article: PMC3549787] [
PubMed: 22789023] [
CrossRef]
- 97.
Gierisch
JM, Nieuwsma
JA, Bradford
DW, Wilder
CM, Mann-Wrobel
MC, McBroom
AJ, et al.
Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry
2014;75:e424–40. 10.4088/JCP.13r08558 [
PubMed: 24922495] [
CrossRef]
- 98.
Maayan
L, Vakhrusheva
J, Correll
CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology
2010;35:1520–30. 10.1038/npp.2010.21 [
PMC free article: PMC3055458] [
PubMed: 20336059] [
CrossRef]
- 99.
- 100.
Hunt
GE, Siegfried
N, Morley
K, Sitharthan
T, Cleary
M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev
2013;10:CD001088. 10.1002/14651858.CD001088.pub3 [
PubMed: 24092525] [
CrossRef]
- 101.
Blackburn
R, Osborn
D, Walters
K, Nazareth
I, Petersen
I. Statin prescribing for prevention of cardiovascular disease amongst people with severe mental illness: cohort study in UK primary care. Schizophr Res
2018;192:219–25. 10.1016/j.schres.2017.05.028 [
PubMed: 28599749] [
CrossRef]
- 102.
Blackburn
R, Osborn
D, Walters
K, Falcaro
M, Nazareth
I, Petersen
I. Statin prescribing for people with severe mental illnesses: a staggered cohort study of ‘real-world’ impacts. BMJ Open
2017;7:e013154. 10.1136/bmjopen-2016-013154 [
PMC free article: PMC5353294] [
PubMed: 28270387] [
CrossRef]
- 103.
Public Health England. Action on Cardiovascular Disease: Getting Serious about Prevention. London: Public Health England; 2016.
- 104.
- 105.
Gray
B, Basset
T, Larsen
J, Faulkner
A. Third sector facilitation of lived experience in research: a case study of service user and carer involvement in the PRIMROSE project. J Ment Health Train Educ Pract
2013;8:141–51. 10.1108/JMHTEP-03-2013-0008 [
CrossRef]
- 106.
Osborn
D, Burton
A, Walters
K, Nazareth
I, Heinkel
S, Atkins
L, et al.
Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled trial. Trials
2016;17:80. 10.1186/s13063-016-1176-9 [
PMC free article: PMC4751703] [
PubMed: 26868949] [
CrossRef]
- 107.
Osborn
D, Burton
A, Hunter
R, Marston
L, Atkins
L, Barnes
T, et al.
Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial. Lancet Psychiatr
2018;5:145–54. 10.1016/S2215-0366(18)30007-5 [
PubMed: 29396118] [
CrossRef]
- 108.
- 109.
Hardeman
W, Michie
S, Fanshawe
T, Prevost
AT, Mcloughlin
K, Kinmonth
AL. Fidelity of delivery of a physical activity intervention: predictors and consequences. Psychol Health
2008;23:11–24. 10.1080/08870440701615948 [
PubMed: 25159904] [
CrossRef]
- 110.
Harting
J, van Assema
P, van der Molen
HT, Ambergen
T, de Vries
NK. Quality assessment of health counseling: performance of health advisors in cardiovascular prevention. Patient Educ Couns
2004;54:107–18. 10.1016/S0738-3991(03)00194-0 [
PubMed: 15210268] [
CrossRef]
- 111.
Barnes
TR, Paton
C, Cavanagh
MR, Hancock
E, Taylor
DM, UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull
2007;33:1397–403. 10.1093/schbul/sbm038 [
PMC free article: PMC2779874] [
PubMed: 17483101] [
CrossRef]
- 112.
De Hert
M, Correll
CU, Bobes
J, Cetkovich-Bakmas
M, Cohen
D, Asai
I, et al.
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry
2011;10:52–77. 10.1002/j.2051-5545.2011.tb00014.x [
PMC free article: PMC3048500] [
PubMed: 21379357] [
CrossRef]
- 113.
Gubbins
A, Lally
J, McDonald
C. Metabolic syndrome in patients attending psychiatric day centres: prevalence and associations. Psychiatrist
2012;36:326–31. 10.1192/pb.bp.111.037374 [
CrossRef]
- 114.
- 115.
Hanssens
L, De Hert
M, Kalnicka
D, van Winkel
R, Wampers
M, Van Eyck
D, et al.
Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol
2007;22:43–9. [
PubMed: 17159459]
- 116.
Landry
P, Dimitri
E, Tessier
S, Legare
N. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. J Clin Psychopharmacol
2008;28:348–9. 10.1097/JCP.0b013e3181727592 [
PubMed: 18480696] [
CrossRef]
- 117.
Ojala
K, Repo-Tiihonen
E, Tiihonen
J, Niskanen
L. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol
2008;22:33–8. 10.1177/0269881107077815 [
PubMed: 17715204] [
CrossRef]
- 118.
Blackburn
RM. Exploring the Effectiveness of Statins for Primary Prevention of Cardiovascular Disease in People with Severe Mental Illness. London: University College London; 2016.
- 119.
- 120.
Chwastiak
L, Fortney
J. Learning to integrate cardiometabolic care in serious mental illness. Am J Psychiatry
2017;174:199–201. 10.1176/appi.ajp.2016.16121399 [
PubMed: 28245694] [
CrossRef]
- 121.
Hippisley-Cox
J, Coupland
C, Brindle
P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ
2017;357:j2099. 10.1136/bmj.j2099 [
PMC free article: PMC5441081] [
PubMed: 28536104] [
CrossRef]
- 122.
Osborn
D, Walters
K. Re: Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ
2017;357:j2099. [
PMC free article: PMC5441081] [
PubMed: 28536104]
- 123.
Staley
K. A Series of Case Studies Illustrating the Impact of Service User and Carer Involvement on Research. London: NIHR Clinical Research Network: Mental Health; 2013.
- 124.
Parks
J, Svendsen
D, Singer
P, Foti
ME. Morbidity and Mortality in People with Serious Mental Illness. Alexandria, VA: National Association of State Mental Health Program Directors Medical Directors Council; 2006.
- 125.
National Institute for Health and Care Excellence (NICE). Methods for the Development of NICE Public Health Guidance. 2nd edn.
London: NICE; 2009. [
PubMed: 27905711]
- 126.
- 127.
Scottish Intercollegiate Guidelines Network (SIGN). Management of Schizophrenia. Edinburgh: SIGN; 2013.
- 128.
Michie
S, Abraham
C. Advancing the science of behaviour change: a plea for scientific reporting. Addiction
2008;103:1409–10. 10.1111/j.1360-0443.2008.02291.x [
PubMed: 18783495] [
CrossRef]
- 129.
Boutron
I, Moher
D, Altman
DG, Schulz
KF, Ravaud
P, CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med
2008;148:295–309. 10.7326/0003-4819-148-4-200802190-00008 [
PubMed: 18283207] [
CrossRef]
- 130.
- 131.
Bellg
AJ, Borrelli
B, Resnick
B, Hecht
J, Minicucci
DS, Ory
M, et al.
Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. Health Psychol
2004;23:443–51. 10.1037/0278-6133.23.5.443 [
PubMed: 15367063] [
CrossRef]
- 132.
Borrelli
B, Sepinwall
D, Ernst
D, Bellg
AJ, Czajkowski
S, Breger
R, et al.
A new tool to assess treatment fidelity and evaluation of treatment fidelity across 10 years of health behavior research. J Consult Clin Psychol
2005;73:852–60. 10.1037/0022-006X.73.5.852 [
PubMed: 16287385] [
CrossRef]
- 133.
- 134.
Craig
P, Dieppe
P, Macintyre
S, Michie
S, Nazareth
I, Petticrew
M, Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ
2008;337:a1655. 10.1136/bmj.a1655 [
PMC free article: PMC2769032] [
PubMed: 18824488] [
CrossRef]
- 135.
Perepletchikova
F, Treat
TA, Kazdin
AE. Treatment integrity in psychotherapy research: analysis of the studies and examination of the associated factors. J Consult Clin Psychol
2007;75:829–41. 10.1037/0022-006X.75.6.829 [
PubMed: 18085901] [
CrossRef]
- 136.
Michie
S. What works and how? Designing more effective interventions needs answers to both questions. Addiction
2008;103:886–7. 10.1111/j.1360-0443.2007.02112.x [
CrossRef]
- 137.
Michie
S, Wood
CE, Johnston
M, Abraham
C, Francis
JJ, Hardeman
W. Behaviour change techniques: the development and evaluation of a taxonomic method for reporting and describing behaviour change interventions (a suite of five studies involving consensus methods, randomised controlled trials and analysis of qualitative data). Health Technol Assess
2015;19(99). 10.3310/hta19990 [
PMC free article: PMC4781650] [
PubMed: 26616119] [
CrossRef]
- 138.
Michie
S, Hyder
N, Walia
A, West
R. Development of a taxonomy of behaviour change techniques used in individual behavioural support for smoking cessation. Addict Behav
2011;36:315–19. 10.1016/j.addbeh.2010.11.016 [
PubMed: 21215528] [
CrossRef]
- 139.
- 140.
Michie
S, Ashford
S, Sniehotta
FF, Dombrowski
SU, Bishop
A, French
DP. A refined taxonomy of behaviour change techniques to help people change their physical activity and healthy eating behaviours: the CALO-RE taxonomy. Psychol Health
2011;26:1479–98. 10.1080/08870446.2010.540664 [
PubMed: 21678185] [
CrossRef]
- 141.
Noell
G, Gresham
F, Gansle
K. Does treatment integrity matter? A preliminary investigation of instructional implementation and mathematical performance. J Behav Educ
2002;11:51–67. 10.1023/A:1014385321849 [
CrossRef]
- 142.
Holcombe
A, Wolery
M, Snyder
E. Effects of two levels of procedural fidelity with constant time delay on children’s learning. J Behav Educ
1994;4:49–73. 10.1007/BF01560509 [
CrossRef]
- 143.
Sweeney-Magee
M, Kale
D, Galton
S, Hamill
A, Gilbert
H. Assessing the fidelity of delivery of an intervention to increase attendance at the English Stop Smoking Services. Implement Sci
2016;11:166. 10.1186/s13012-016-0498-z [
PMC free article: PMC5192595] [
PubMed: 28031035] [
CrossRef]
- 144.
- 145.
Schlosser
R. On the importance of being earnest about treatment integrity. Augment Altern Commun
2002;18:36–44. 10.1080/aac.18.1.36.44 [
CrossRef]
- 146.
Gresham
FM. Treatment integrity in single-subject research. In Franklin
RD, Allison
DB, Gorman
BS, editors. Design and Analysis of Single-case Research. Mahwah, NJ: Lawrence Erlbaum Associates; 1996.
- 147.
Burke
LE, Fair
J. Promoting prevention. Skills sets and attributes of health care providers who deliver behavioural interventions. J Cardiovasc Nurs
2003;18:256–66. 10.1097/00005082-200309000-00004 [
PubMed: 14518601] [
CrossRef]
